Identification of an RNA aptamer binding hTERT-derived peptide and inhibiting telomerase activity in MCF7 cells

• DOI: 10.1007/s11010-016-2907-7
• Publication Date: 2016-12-21T02:03:47Z
• Authors: Akhil Varshney; Jyoti Bala; Baby Santosh; Ashima Bhaskar; Suresh Kumar; Pramod K. Yadava
• Keywords: 0301 basic medicine; 03 medical and health sciences; Protein Domains; MCF-7 Cells; Humans; Female; Aptamers, Nucleotide; Oligopeptides; Telomerase; Neoplasm Proteins; 3. Good health

Human telomerase reverse transcriptase is an essential rate-limiting component of telomerase complex. hTERT protein in association with other proteins and the human telomerase RNA (hTR) shows telomerase activity, essential for maintaining genomic integrity in proliferating cells. hTERT binds hTR through a decapeptide located in the RID2 (RNA interactive domain 2) domain of N-terminal region. Since hTERT is essential for telomerase activity, inhibitors of hTERT are of great interest as potential anti-cancer agent. We have selected RNA aptamers against a synthetic peptide from the RID2 domain of hTERT by employing in vitro selection protocol (SELEX). The selected RNAs could bind the free peptide, as CD spectra suggested conformational change in aptamer upon RID2 binding. Extracts of cultured breast cancer cells (MCF7) expressing this aptamer showed lower telomerase activity as estimated by TRAP assay. hTERT-binding RNA aptamers hold promise as probable anti-cancer therapeutic agent.